FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1894305891> ?p ?o ?g. }

• W1894305891 endingPage "395" @default.
• W1894305891 startingPage "387" @default.
• W1894305891 abstract "Summary. Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available on the safety of combination therapy with nucleos(t)ide analogues and interferon alfa (IFNα). The aim of this analysis was to assess the renal function during combination therapy with peginterferon alfa-2a (PegIFNα-2a) plus ADV vs either drug alone in patients with hepatitis B/D co-infection. We performed a retrospective analysis of renal function data of patients treated in the Hep-Net/International Delta Hepatitis Intervention Trial 1(HIDIT-1-trial), a European multicenter study to investigate the efficacy of 48 weeks of therapy with PegIFNα-2a+ADV vs either drug alone in 90 patients with chronic hepatitis B/D co-infection. Glomerular filtration rates (GFR) were calculated by Cockcroft–Gault (CG), abbreviated Modification of Diet in Renal Disease (MDRD) study and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. After 48 weeks of therapy GFR values were significantly lower in patients receiving adefovir-containing treatment vs PegIFNα-2a alone [mean difference 16.1 mL/min (CG) and 10.2 mL/min (MDRD), respectively, P < 0.05] while no differences were observed between patients receiving adefovir alone vs combination treatment. Twenty-four weeks after treatment GFR values did not differ between treatment arms. A decrease in GFR ≥20% was observed more often in patients during adefovir-containing treatment vs PegIFNα-2a alone (P < 0.05) which was confirmed by Kaplan–Meier analysis. Adefovir-containing but not PegIFNα-2a treatment was associated with a decrease in GFR values in about one-fifth of patients. Combination treatment of PegIFNα-2a+ADV in chronic hepatitis B/D co-infection did not lead to any further impairment of kidney function." @default.
• W1894305891 created "2016-06-24" @default.
• W1894305891 creator A5002183557 @default.
• W1894305891 creator A5006198673 @default.
• W1894305891 creator A5009238813 @default.
• W1894305891 creator A5010614894 @default.
• W1894305891 creator A5012052658 @default.
• W1894305891 creator A5024219904 @default.
• W1894305891 creator A5032723172 @default.
• W1894305891 creator A5033769750 @default.
• W1894305891 creator A5036482660 @default.
• W1894305891 creator A5045504446 @default.
• W1894305891 creator A5052738922 @default.
• W1894305891 creator A5076739762 @default.
• W1894305891 creator A5077245179 @default.
• W1894305891 creator A5088602858 @default.
• W1894305891 date "2011-12-19" @default.
• W1894305891 modified "2023-10-14" @default.
• W1894305891 title "Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection" @default.
• W1894305891 cites W1550111394 @default.
• W1894305891 cites W1814037092 @default.
• W1894305891 cites W1963687802 @default.
• W1894305891 cites W1966807894 @default.
• W1894305891 cites W1985437256 @default.
• W1894305891 cites W1986864408 @default.
• W1894305891 cites W1997681955 @default.
• W1894305891 cites W1999664635 @default.
• W1894305891 cites W2008517556 @default.
• W1894305891 cites W2009509017 @default.
• W1894305891 cites W2009854047 @default.
• W1894305891 cites W2025879508 @default.
• W1894305891 cites W2028175659 @default.
• W1894305891 cites W2031317669 @default.
• W1894305891 cites W2032063600 @default.
• W1894305891 cites W2055864845 @default.
• W1894305891 cites W2071993332 @default.
• W1894305891 cites W2089153567 @default.
• W1894305891 cites W2101032357 @default.
• W1894305891 cites W2107195787 @default.
• W1894305891 cites W2146105386 @default.
• W1894305891 cites W2149836081 @default.
• W1894305891 cites W2155965977 @default.
• W1894305891 cites W2157039129 @default.
• W1894305891 cites W3030265267 @default.
• W1894305891 doi "https://doi.org/10.1111/j.1365-2893.2011.01560.x" @default.
• W1894305891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22571900" @default.
• W1894305891 hasPublicationYear "2011" @default.
• W1894305891 type Work @default.
• W1894305891 sameAs 1894305891 @default.
• W1894305891 citedByCount "7" @default.
• W1894305891 countsByYear W18943058912012 @default.
• W1894305891 countsByYear W18943058912014 @default.
• W1894305891 countsByYear W18943058912015 @default.
• W1894305891 countsByYear W18943058912016 @default.
• W1894305891 countsByYear W18943058912017 @default.
• W1894305891 countsByYear W18943058912018 @default.
• W1894305891 countsByYear W18943058912022 @default.
• W1894305891 crossrefType "journal-article" @default.
• W1894305891 hasAuthorship W1894305891A5002183557 @default.
• W1894305891 hasAuthorship W1894305891A5006198673 @default.
• W1894305891 hasAuthorship W1894305891A5009238813 @default.
• W1894305891 hasAuthorship W1894305891A5010614894 @default.
• W1894305891 hasAuthorship W1894305891A5012052658 @default.
• W1894305891 hasAuthorship W1894305891A5024219904 @default.
• W1894305891 hasAuthorship W1894305891A5032723172 @default.
• W1894305891 hasAuthorship W1894305891A5033769750 @default.
• W1894305891 hasAuthorship W1894305891A5036482660 @default.
• W1894305891 hasAuthorship W1894305891A5045504446 @default.
• W1894305891 hasAuthorship W1894305891A5052738922 @default.
• W1894305891 hasAuthorship W1894305891A5076739762 @default.
• W1894305891 hasAuthorship W1894305891A5077245179 @default.
• W1894305891 hasAuthorship W1894305891A5088602858 @default.
• W1894305891 hasBestOaLocation W18943058911 @default.
• W1894305891 hasConcept C126322002 @default.
• W1894305891 hasConcept C126894567 @default.
• W1894305891 hasConcept C159641895 @default.
• W1894305891 hasConcept C203014093 @default.
• W1894305891 hasConcept C2522874641 @default.
• W1894305891 hasConcept C2776999253 @default.
• W1894305891 hasConcept C2777382497 @default.
• W1894305891 hasConcept C2777869810 @default.
• W1894305891 hasConcept C2778653478 @default.
• W1894305891 hasConcept C2779517838 @default.
• W1894305891 hasConcept C2992208098 @default.
• W1894305891 hasConcept C3020491458 @default.
• W1894305891 hasConcept C71924100 @default.
• W1894305891 hasConcept C90924648 @default.
• W1894305891 hasConceptScore W1894305891C126322002 @default.
• W1894305891 hasConceptScore W1894305891C126894567 @default.
• W1894305891 hasConceptScore W1894305891C159641895 @default.
• W1894305891 hasConceptScore W1894305891C203014093 @default.
• W1894305891 hasConceptScore W1894305891C2522874641 @default.
• W1894305891 hasConceptScore W1894305891C2776999253 @default.
• W1894305891 hasConceptScore W1894305891C2777382497 @default.
• W1894305891 hasConceptScore W1894305891C2777869810 @default.
• W1894305891 hasConceptScore W1894305891C2778653478 @default.
• W1894305891 hasConceptScore W1894305891C2779517838 @default.
• W1894305891 hasConceptScore W1894305891C2992208098 @default.

• next